The FDA recently published a draft guidance document for “Drug Products, Including Biological Products, that Contain Nanomaterials.” The draft guidance document can be...
Nanotechnology Characterization Lab
Eliminating suffering and death from cancer requires an unprecedented collaborative effort that leverages resources from government, industry, and academia. Working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI) established the Nanotechnology Characterization Laboratory to perform preclinical efficacy and toxicity testing of nanoparticles.
The NCL serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services to nanomaterial providers, the NCL accelerates the transition of basic nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer.
There are multiple ways the NCL can help nanotech researchers and developers advance their technology, including characterization, reformulation, optimization, lead selection, method development, and more.
News & Updates
Each quarter the NCL accepts the most promising cancer nanomedicine candidates into its Assay Cascade characterization and testing program.
The NCL has recently published a follow-on book to its Characterization of nanoparticles intended for drug delivery.
- 1 of 3
- next ›
Meet Us @
The 34th Southern Biomedical Engineering Conference is being held in Charlotte, NC, March 8-10, 2018. Dr. Marina Dobrovolskaia will speak at the meeting.
The 2018 annual SOT meeting will take place in San Antonio, TX, March 11-15. Dr. Stephan Stern, PhD, DABT will be presenting.